<html><body><h2>Case: 1287695832065</h2>
89.0 year old Hispanic White Male
<p><b>Lab & Note Entry Values:</b> <table>
<b><tr><td width="200">Lab</td><td width="200">Value</td><td width="200">Date</td></tr></b>
<tr><td width="200">Weight</td><td width="200">170</td><td width="200">2010-8-20</td></tr>
<tr><td width="200">Systolic_BP</td><td width="200">134</td><td width="200">2010-6-18</td></tr>
<tr><td width="200">Potassium</td><td width="200">5</td><td width="200">2010-8-20</td></tr>
<tr><td width="200">HbA1C</td><td width="200">8</td><td width="200">2010-8-20</td></tr>
<tr><td width="200">HDL_Cholesterol</td><td width="200">38</td><td width="200">2010-8-20</td></tr>
<tr><td width="200">Left Ventricular Ejection fraction</td><td width="200">33</td><td width="200">2010-8-17</td></tr>
<tr><td width="200">Diastolic_BP</td><td width="200">62</td><td width="200">2010-6-18</td></tr>
<tr><td width="200">Creatinine</td><td width="200">1.4</td><td width="200">2010-8-20</td></tr>
<tr><td width="200">LDL_Cholesterol</td><td width="200">120</td><td width="200">2010-8-20</td></tr>
<tr><td width="200">Pulse</td><td width="200">71</td><td width="200">2010-6-18</td></tr>
<tr><td width="200">Age</td><td width="200">89</td><td width="200">1970-1-1</td></tr>
<tr><td width="200">DM-Type2</td><td width="200">Diabetes Type 2</td><td width="200">2010-6-18</td></tr>
<tr><td width="200">Disorders Lipid Metabolism</td><td width="200">Hyperlipidemia</td><td width="200">2010-6-18</td></tr>
<tr><td width="200">Myocardial_Infarction</td><td width="200">Myocardial Infarction</td><td width="200">2010-6-18</td></tr>
<tr><td width="200">Coronary_Artery_Disease</td><td width="200">Coronary Artery Disease</td><td width="200">2010-6-18</td></tr>
<tr><td width="200">Heart_Failure</td><td width="200">Heart Failure</td><td width="200">2010-6-18</td></tr>
<tr><td width="200">Hypertension</td><td width="200">Hypertension</td><td width="200">2010-6-18</td></tr>
<tr><td width="200">NYHA functional class II</td><td width="200"></td><td width="200">2010-8-17</td></tr>
<tr><td width="200">Height</td><td width="200">5'8</td><td width="200">2010-8-20</td></tr>
<tr><td width="200">Race</td><td width="200">Hispanic White</td><td width="200"></td></tr>
<tr><td width="200">Sex</td><td width="200">Male</td><td width="200"></td></tr>
</table>
<p><b>Medications:</b> nitrate(0.4) METFORMIN(1000.0) lisinopril(20.0) atorvastatin(10.0) 
<p><b>Problems:</b> <table>
<tr><td width="200"><b>Problem Class</b></td><td width="200"><b>First/Last Dates Reported</b></td><td width="200"></td></tr>
<tr><td width="200">Target_Organ_Damage_Clinical_Cardiovascular_Disease</td>
<td width="200"></td>
<td width="200"> TOD/CCD[presence of myocardial infarction]()</td></tr>
<tr><td width="200">Dyslipidemia Lab criteria</td>
<td width="200"></td>
<td width="200"> Dyslipidemia Lab criteria[HDL_Cholesterol(38.0/2010-8-20)]()</td></tr>
<tr><td width="200">Diabetes WITHOUT proteinuria/renal manifestations</td>
<td width="200"></td>
<td width="200"> Diabetes[presence of diabetes mellitus && Absence of diabetic with renal manifestations && Absence of diabetic nephropathy && Absence of diabetic nephrosis && Proteinuria equals trace or above && Absence of ARB]()</td></tr>
<tr><td width="200">DM (2ary prev)  BP controlled</td>
<td width="200"></td>
<td width="200"> Diabetes (Secondary Prevention)[Treatment_Diastolic_BP(62/null) && Treatment_Systolic_BP(134/null) && presence of diabetes mellitus]()</td></tr>
<tr><td width="200">Heart Failure  (Secondary Prev) BP controlled</td>
<td width="200"></td>
<td width="200"> Heart Failure (Secondary Prevention)[Treatment_Diastolic_BP(62/null) && Treatment_Systolic_BP(134/null) && presence of heart failure]()</td></tr>
<tr><td width="200">MI (secondary prevention) BP controlled</td>
<td width="200"></td>
<td width="200"> Myocardial Infarction (Secondary Prevention)[Treatment_Diastolic_BP(62/null) && Treatment_Systolic_BP(134/null) && presence of myocardial infarction]()</td></tr>
<tr><td width="200">Heart Failure (second prev) BP cont</td>
<td width="200"></td>
<td width="200"> Heart Failure (Secondary prevention)[Treatment_Diastolic_BP(62/null) && Treatment_Systolic_BP(134/null) && heart failure present]()</td></tr>
<tr><td width="200">DM</td>
<td width="200"></td>
<td width="200"> Diabetes[presence of diabetes mellitus]()</td></tr>
<tr><td width="200">Major Cardiovascular Risk Factor</td>
<td width="200"></td>
<td width="200"> Major Cardiovascular Risk Factor[Age(89.0/1970-1-1) && Sex(Male)]()</td></tr>
<tr><td width="200">Dyslipidemia Lab or ICD9</td>
<td width="200"></td>
<td width="200"> Dyslipidemia Lab or ICD9[presence of dyslipidemia lab criteria]()</td></tr>
<tr><td width="200">Age > 65</td>
<td width="200"></td>
<td width="200"> age > 65 years[Age(89.0/1970-1-1)]()</td></tr>
<tr><td width="200">on >= 1 med</td>
<td width="200"></td>
<td width="200"> Combination therapy for HTN[Antihypertensive_Agents]()</td></tr>
<tr><td width="200">On 1 drug and there exists contraindicated drug or a compelling drug not given</td>
<td width="200"></td>
<td width="200"> On 1 drug and there exists contraindicated drug or a compelling drug not given[there exists a compellingly indicated drug that is not already given]()</td></tr>
<tr><td width="200">Hypertension with MI and K>=3.5</td>
<td width="200"></td>
<td width="200"> Hypertension with MI and K>=3.5[Potassium(4.6/2010-8-20) && presence of MI]()</td></tr>
<tr><td width="200">HF (ICD or Symptoms) and LVEF<=40 and MI</td>
<td width="200"></td>
<td width="200"> HF (ICD or Symptoms) and LVEF<=40 and MI[heart failure present && Left Ventricular Ejection fraction(33.0/2010-8-17) && Presence of MI]()</td></tr>
<tr><td width="200">Absence of Stage D HF</td>
<td width="200"></td>
<td width="200"> Absence of Stage D HF[NOT refractory end stage HF (Stage D)Stage D HF (refractory end stage HF)]()</td></tr>
<tr><td width="200">LVEF<=40</td>
<td width="200"></td>
<td width="200"> LV Ejection Fraction <= 40[Left Ventricular Ejection fraction(33.0/2010-8-17)]()</td></tr>
<tr><td width="200">High Risk for HF and DM, HTN, or atherosclerotic vascular disease</td>
<td width="200"></td>
<td width="200"> High Risk for HF and DM, HTN, or atherosclerotic vascular disease[diabetes_mellitus]()</td></tr>
<tr><td width="200">HF (ICD9 or symptoms) and LVEF<=40</td>
<td width="200"></td>
<td width="200"> HF (ICD9 or symptoms) and LVEF<=40[Left Ventricular Ejection fraction(33.0/2010-8-17) && heart failure present]()</td></tr>
<tr><td width="200">CCS-7.2</td>
<td width="200">2010-06-18</td>
<td width="200"> Myocardial_Infarction()</td></tr>
<tr> <td width="200"></td>
<td width="200">2010-06-18</td>
<td width="200"> Heart_Failure()</td></tr>
<tr> <td width="200"></td>
<td width="200">2010-06-18</td>
<td width="200"> Coronary_Artery_Disease()</td></tr>
<tr> <td width="200"></td>
<td width="200"></td>
<td width="200"> LV Ejection Fraction <= 40[Left Ventricular Ejection fraction(33.0/2010-8-17)]()</td></tr>
<tr> <td width="200"></td>
<td width="200"></td>
<td width="200"> Low ejection fraction (<40)[Left Ventricular Ejection fraction(33.0/2010-8-17)]()</td></tr>
<tr><td width="200">Hypertension_Inclusive</td>
<td width="200">2010-06-18</td>
<td width="200"> Hypertension()</td></tr>
<tr> <td width="200"></td>
<td width="200"></td>
<td width="200"> Hypertension with MI and K>=3.5[Potassium(4.6/2010-8-20) && presence of MI]()</td></tr>
<tr><td width="200">Metabolic&Nutritional_Diseases</td>
<td width="200">2010-06-18</td>
<td width="200"> Disorders Lipid Metabolism()</td></tr>
<tr><td width="200">Endocrine_Diseases</td>
<td width="200">2010-06-18</td>
<td width="200"> DM-Type2()</td></tr>
<tr><td width="200">Hypertension_Defined</td>
<td width="200"></td>
<td width="200"> Hypertension with MI and K>=3.5[Potassium(4.6/2010-8-20) && presence of MI]()</td></tr>
<tr><td width="200">Age>80 yrs</td>
<td width="200"></td>
<td width="200"> Age>80yrs[Age(89.0/1970-1-1)]()</td></tr>
<tr><td width="200">High Risk Group</td>
<td width="200"></td>
<td width="200"> High Risk Group[Presence of hypertension]()</td></tr>
<tr><td width="200">Age>65?</td>
<td width="200"></td>
<td width="200"> Age>65?[Age(89.0/1970-1-1)]()</td></tr>
<tr><td width="200"> <b>Others</b></td>
<td width="200"></td>
<td width="200"> Sex()
<tr> <td width="200"></td>
<td width="200"></td>
<td width="200"> Race()
<tr> <td width="200"></td>
<td width="200">2010-08-20</td>
<td width="200"> Height()
<tr> <td width="200"></td>
<td width="200">2010-08-17</td>
<td width="200"> NYHA functional class II()
</table><p>
<h1 align="center">ATHENA Heart Failure Guideline</h1>
<b>Patient classification:</b> <ul>
<li>ATHENA Heart Failure Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(NOT refractory end stage HF (Stage D)Stage D HF (refractory end stage HF))</i>]
</ul>
<b>Scenario choice:</b> Stage C HF
<p>
<b>Goal:</b> LDL< 100 mg/dL(CHD Risk Equivalent)
<p><b>Reached goal?</b> failed(LDL_Cholesterol(120.0/2010-8-20))
<p>
<b>Goal:</b> SBP < 140 and DBP < 80(presence of diabetes mellitus)
<p><b>Reached goal?</b> achieved(Treatment_Diastolic_BP(62/null) && Treatment_Systolic_BP(134/null))
<p><b>Messages by Types</b>
<ul>
<li><b>Class III</b>
<ul>
<li>Use of NUTRITIONAL SUPPLEMENTS as treatment for HF is NOT INDICATED in patients with current or prior symptoms of HF and reduced LVEF. (Level of Evidence: C)
<li>HORMONAL THERAPIES other than to replete deficiencies are NOT RECOMMENDED and may be harmful to patients with current or prior symptoms of HF and reduced LVEF. (Level of Evidence: C)
<li>Use of nutritional supplements to treat structural heart disease or to prevent the development of symptoms of HF is NOT recommended.
</ul>
<li><b>Class II a</b>
<ul>
<li>Maximal exercise testing with or without measurement of respiratory gas exchange is reasonable to facilitate prescription of an appropriate exercise program for patients presenting with HF. (Level of Evidence: C)
</ul>
<li><b>Class I</b>
<ul>
<li>Exercise training is beneficial as an adjunctive approach to improve clinical status in ambulatory patients with current or prior symptoms of HF and reduced LVEF. (Level of Evidence: B)
<li>Diuretics and salt restriction are indicated if there is evidence of fluid retention. (Level of Evidence: C)
<li>Coronary revascularization should be recommended in appropriate patients without symptoms of HF in accordance with contemporary guidelines (see ACC/AHA/ACP-ASIM Guidelines for the Management of Patients With Chronic Stable Angina).
</ul>
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Stage C HF</b><br>
<ul>
<li><b>Blood sugar control <font color=FF0000>preferred</font></b>(rule in criterion<i> diabetes_mellitus</i> evaluate to <b> true</b> because <i>diabetes_mellitus</i>)])
For patients with diabetes mellitus (who are all at high risk for
developing HF), blood sugar should be controlled in accordance
with contemporary guidelines. (Level of Evidence: C)
<li><b>behavior control <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Patients at high risk for developing HF should be counseled to
avoid behaviors that may increase the risk of HF (e.g., smoking,
excessive alcohol consumption, and illicit drug use). (Level of
Evidence: C)
<li><b>Periodic evaluation <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Healthcare providers should perform periodic evaluation for signs
and symptoms of HF in patients at high risk for developing HF.
(Level of Evidence: C)
<li><b>Lipid disorder control <font color=FF0000>preferred</font></b>(rule in criterion<i> Lipid not under control</i> evaluate to <b> true</b> because <i>Lipid not under controlLDL_Cholesterol(120.0/2010-8-20)</i>)])
In patients at high risk for developing HF, lipid disorders should
be treated in accordance with contemporary guidelines. (Level of
Evidence: A)
</ul>
<li><b> </b><br>
<ul>
<li><b>General Recommendations <font color=FF0000>preferred</font></b>(strict rule-in condition<i> HF ICD9 code OR( signs and structural abnormality)</i> evaluate to <b> true</b> because <i>Presence of HF</i>)])
Exercise training is beneficial as an adjunctive approach to improve clinical status in ambulatory patients with current or prior symptoms of HF and reduced LVEF. (Level of Evidence: B)
Maximal exercise testing with or without measurement of respiratory gas exchange is reasonable to facilitate prescription of an appropriate exercise program for patients presenting with HF. (Level of Evidence: C)
Use of NUTRITIONAL SUPPLEMENTS as treatment for HF is NOT INDICATED in patients with current or prior symptoms of HF and reduced LVEF. (Level of Evidence: C)
HORMONAL THERAPIES other than to replete deficiencies are NOT RECOMMENDED and may be harmful to patients with current or prior symptoms of HF and reduced LVEF. (Level of Evidence: C)

Diuretics and salt restriction are indicated if there is evidence of fluid retention. (Level of Evidence: C)
<li><b>Referrals <font color=FF0000>preferred</font></b>(strict rule-in condition<i> true</i> evaluate to <b> true</i>)])
Class I
<li><b>Stage B HF action <font color=FF0000>preferred</font></b>(strict rule-in condition<i> true</i> evaluate to <b> true</i>)])

Use of nutritional supplements to treat structural heart disease or to prevent the development of symptoms of HF is NOT recommended.
Coronary revascularization should be recommended in appropriate patients without symptoms of HF in accordance with contemporary guidelines (see ACC/AHA/ACP-ASIM Guidelines for the Management of Patients With Chronic Stable Angina).
Patient has a low LVEF, consider cardiac evaluation or repeat left ventricular ejection fraction in about 3 months.
</ul>
</ul>
<b>Considerations for adding drug: </b><ul>
<li>aldosterone antagonist
<ul>
<li>preference: neutral
<li>No comment
</ul>
<li>hydralazine and nitrates
<ul>
<li>preference: neutral
<li>No comment
</ul>
<li>Beta blocker for stage C heart failure(Carvedilol)
<ul>
<li>preference: neutral
<li>No comment
</ul>
<li>Beta blocker Stage C with MI
<ul>
<li>preference: neutral
<li>No comment
</ul>
</ul>
<b>Considerations for adding drug: </b><ul>
<li>ARB
<ul>
<li>Relative indications:  High Risk for HF and DM, HTN, or atherosclerotic vascular disease(High Risk for HF and DM, HTN, or atherosclerotic vascular disease[diabetes_mellitus]) 
<li>preference: preferred
</ul>
<li>digoxin
<ul>
<li>Relative indications:  HF (ICD9 or symptoms) and LVEF<=40(HF (ICD9 or symptoms) and LVEF<=40[Left Ventricular Ejection fraction(33.0/2010-8-17) && heart failure present]) 
<li>inital dose recommendation digoxin when age>70, egfr<30 or lean body mass.(Initial recommended dose of digoxin is 0.125mcg daily (or every other day).)
<li>parameterized message: dig dose if age>70, egfr<30 or lean body mass
<li>Digoxin StageC Class IIA 4(Digitalis can be beneficial in patients with current or prior symptoms of HF and reduced LVEF to decrease hospitalizations for HF (Level of Evidence: B).  ADD ADDL INFO from HF experts to help guide choice of when to add dig)
<li>preference: preferred
</ul>
<li>Beta blocker stage B post MI(Carvedilol)
<ul>
<li>preference: neutral
<li>No comment
</ul>
<li>Beta Blocker Stage B no MI
<ul>
<li>preference: neutral
<li>No comment
</ul>
<li>Ace_Inhibitor(Captopril, Lisinopril, Enalapril)
<ul>
<li>Already being used
<li><font color=FF0000>Compelling indications:  Myocardial_Infarction(Myocardial_Infarction)  HF (ICD9 or symptoms) and LVEF<=40(HF (ICD9 or symptoms) and LVEF<=40[Left Ventricular Ejection fraction(33.0/2010-8-17) && heart failure present]) </font>
<li>Relative indications:  High Risk for HF and DM, HTN, or atherosclerotic vascular disease(High Risk for HF and DM, HTN, or atherosclerotic vascular disease[diabetes_mellitus]) 
<li>preference: ruled out
</ul>
<li>NDHP CCB
<ul>
<li>Contraindications:  Heart_Failure(Heart_Failure)  Myocardial_Infarction(Myocardial_Infarction)  HF (ICD9 or symptoms) and LVEF<=40(HF (ICD9 or symptoms) and LVEF<=40[Left Ventricular Ejection fraction(33.0/2010-8-17) && heart failure present]) 
<li>preference: ruled out
</ul>
</ul>
<h2>ATHENA CKD Guideline</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA CKD Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(Age(89.0/1970-1-1) && Absence of end-stage renal disease && Absence of kidney transplant && Presence of Diabetes && Presence of hypertension)</i>]
</ul>
<b>Scenario choice:</b> >=1 Cr or mALB/Cr within a year
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Result normal?</b><br>
<ul>
<li><b>No mALB/Cr, Order microalbumin/Cr ratio <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Absence of microalbumin/creatinine but presence of Cr within a year</i> evaluate to <b> true</b> because <i>Absence of microalbumin/creatinine ratio within a year && Presence of Cr within a year</i>)])
Absence of microalbumin/creatinine ratio within a year; please order it now.
</ul>
</ul>
<h2>ATHENA Diabetes Mellitus: Foot Care</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Diabetes Mellitus: Foot Care: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(diabetes_mellitus)</i>]
</ul>
<b>Scenario choice:</b> Not wound-followup DM patients
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Initial assessments</b><br>
<ul>
<li><b>Perform and document foot risk assessment (B) and visual inspection of feet <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])

Perform and document visual inspection of patient's feet.
<li><b>Assess if limb threatening condition present <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])

</ul>
<li><b>Evaluate </b><br>
<ul>
</ul>
</ul>
<h2>ATHENA DM: Eye Care</h2>
<b>Patient classification:</b> <ul>
</ul>
<b>Scenario choice:</b> Eye exam over a year ago or no data
<p><b>Action Choices</b>
<ul>
<li><b>Referral for eye exam over a year or no data</b><br>
<ul>
<li><b>Refer for eye exam within 3m <font color=FF0000>preferred</font></b>(strict rule-in condition<i> DM type 2 newly diagnosed or insulin or ocular risk or diabetes type 1 >= 3 years</i> evaluate to <b> true</b> because <i>diabetes < 15 years</i>)])
Referral should be scheduled for 3 months from today (max)
</ul>
</ul>
<h2>ATHENA DM: Glycemic Control</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA DM: Glycemic Control: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(diabetes_mellitus)</i>]
</ul>
<b>Scenario choice:</b> No target  or no HbA1C
<p><b>Action Choices</b>
<ul>
<li><b>Lack target or lack HbA1C</b><br>
<ul>
<li><b>Determine goal <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Absence Target HBA1c</i> evaluate to <b> true</b> because <i>Absence Target HBA1c</i>)])

<li><b>Order HbA1C <font color=FF0000>preferred</font></b>(strict rule-in condition<i> No HbA1C ever or in past year</i> evaluate to <b> true</b> because <i>Absence of HbA1C lab value in past year</i>)])

</ul>
</ul>
<h2>ATHENA Lipid Management Guideline</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Lipid Management Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(Age(89.0/1970-1-1) && Absence of Pregnancy)</i>]
<li>CHD or CHD-Equivalent: [because <i> CHD Risk Equivalent </i> evaluate to <b>true</b><i>(Presence of diabetes)</i>]
</ul>
<b>Scenario choice:</b> Drug Therapy (1 drug)
<p>
<b>Goal:</b> LDL< 100 mg/dL(CHD Risk Equivalent)
<p><b>Reached goal?</b> failed(LDL_Cholesterol(120.0/2010-8-20))
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>1-drug therapy choice</b><br>
<ul>
<li><b>Intensify <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Not within guideline goal</i> evaluate to <b> true</b> because <i>Not within guideline goalLDL_Cholesterol(120.0/2010-8-20)</i>)])
<b><font color=red>Intensify drug therapy</font>
</ul>
<li><b>Intensify choices</b><br>
<ul>
<li><b>Add drug <font color=FF0000>preferred</font></b>(strict rule-in condition<i> true</i> evaluate to <b> true</i>)])

<li><b>Increase dose <font color=FF0000>preferred</font></b>(strict rule-in condition<i> There exists non-contraindicated drug that is not at maximum dose</i> evaluate to <b> true</b> because <i>There exists non-contraindicated drug that is not at maximum dose</i>)])

</ul>
</ul>
<b>Considerations for adding drug: </b><ul>
<li>Bile Acid Sequestrant
<ul>
<li>Relative indications:  LDL_not_within_guideline_goal(LDL not within guideline goal[Not within guideline goalLDL_Cholesterol(120.0/2010-8-20)]) 
<li>preference: preferred
</ul>
<li>Nicotinic Acid
<ul>
<li>Relative indications:  LDL_not_within_guideline_goal(LDL not within guideline goal[Not within guideline goalLDL_Cholesterol(120.0/2010-8-20)]) 
<li>Relative contraindications:  Diabetes_Mellitus(DM-Type2) 
<li>preference: preferred
</ul>
<li>Fibric Acid
<ul>
<li>preference: neutral
<li>No comment
</ul>
<li>Statin
<ul>
<li>Already being used
<li><font color=FF0000>Compelling indications:  LDL_not_within_guideline_goal(LDL not within guideline goal[Not within guideline goalLDL_Cholesterol(120.0/2010-8-20)]) </font>
<li>preference: ruled out
</ul>
</ul>
<h2>VA/JNC-VII Hypertension Guideline</h2>
<b>Patient classification:</b> <ul>
<li>VA/JNC-VII Hypertension Guideline: unknown[because <i> Eligibility criteria </i> evaluate to <b>unknown</b><i>(eGFR(no value))</i>]
<li>Risk Group C (presence of TOD/CCD or DM): [because <i> presence of TOD/CCD or DM </i> evaluate to <b>true</b><i>(presence of DM)</i>]
</ul>
<b>Scenario choice:</b> on one anti-hypertensive drug
<p>
<b>Goal:</b> SBP < 140 and DBP < 80(presence of diabetes mellitus)
<p><b>Reached goal?</b> achieved(Treatment_Diastolic_BP(62/null) && Treatment_Systolic_BP(134/null))
<p><b>Messages by Types</b>
<ul>
<li><b>Assumption</b>
<ul>
<li>We did not find a BP in the vitals signs section of the computer.  We are not at present able to use the BP recorded in the text of the progress note, so we are not able to determine whether the BP control is adequate or inadequate.  Please enter BP using the top part of the screen.
</ul>
<li><b>Primary_Recommendation</b>
<ul>
<li>Maintain current drug choices and  continue to encourage patient adherence to his/her current regimen.
</ul>
<li><b>Recommendation</b>
<ul>
<li>It is true that 7.3 inches of rain fell yesterday, and the patient is taking the following drugs: nitrate, lisinopril, METFORMIN, atorvastatin
<li>The clinical information from this system is advisory only and is intended to supplement the knowledge of health care professionals regarding the management of hypertension. It is not intended to replace sound clinical judgment or individualized patient care in delivery of healthcare services.
  Although the ATHENA-HTN information is derived from research literature and is subject to review, we cannot guarantee its comprehensiveness or currency. Please note that medical information is dynamic due to ongoing research and clinical experience and is subject to interpretation. There is also the possibility of errors in the programming.  The user of this software assumes sole responsibility for any decisions made or actions taken based the information contained in this software, including but not limited to therapeutic suggestions.  ATHENA-HTN, the Department of Veterans Affairs and Stanford University shall have no liability to any person, or entity with regard to claims, loss, or damage caused, or alleged to be caused, directly or indirectly by the use of this software or the information contained within.  ATHENA-HTN is the property of Stanford's Office Technology Licensing (OTL) and Department of Veterans Affairs.  
By accessing ATHENA-HTN, you agree use ATHENA-HTN only as a reference resource for research. You agree to abstain from using ATHENA-HTN to generate knowledge for treatment.
</ul>
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>on medication: things to check</b><br>
<ul>
<li><b>assumption  check presence of BP <font color=FF0000>preferred</font></b>(rule in criterion<i> diastolic BP or systolic BP absent</i> evaluate to <b> true</b> because <i>absence of diastolic BP</i>)])
We did not find a BP in the vitals signs section of the computer.  We are not at present able to use the BP recorded in the text of the progress note, so we are not able to determine whether the BP control is adequate or inadequate.  Please enter BP using the top part of the screen.
<li><b>adverse event warning <font color=FF0000>preferred</font></b>(rule in criterion<i> presence of current medication with adverse reaction</i> evaluate to <b> true</b> because <i>presence of current medication with adverse reaction</i>)])
<li><b>test parameterized message <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
It is true that 7.3 inches of rain fell yesterday, and the patient is taking the following drugs: nitrate, lisinopril, METFORMIN, atorvastatin
<li><b>Disclaimer <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
The clinical information from this system is advisory only and is intended to supplement the knowledge of health care professionals regarding the management of hypertension. It is not intended to replace sound clinical judgment or individualized patient care in delivery of healthcare services.
  Although the ATHENA-HTN information is derived from research literature and is subject to review, we cannot guarantee its comprehensiveness or currency. Please note that medical information is dynamic due to ongoing research and clinical experience and is subject to interpretation. There is also the possibility of errors in the programming.  The user of this software assumes sole responsibility for any decisions made or actions taken based the information contained in this software, including but not limited to therapeutic suggestions.  ATHENA-HTN, the Department of Veterans Affairs and Stanford University shall have no liability to any person, or entity with regard to claims, loss, or damage caused, or alleged to be caused, directly or indirectly by the use of this software or the information contained within.  ATHENA-HTN is the property of Stanford's Office Technology Licensing (OTL) and Department of Veterans Affairs.  
By accessing ATHENA-HTN, you agree use ATHENA-HTN only as a reference resource for research. You agree to abstain from using ATHENA-HTN to generate knowledge for treatment.
</ul>
<li><b>one-drug-therapy-choices</b><br>
<ul>
<li><b>continue with one-drug regimen <font color=FF0000>preferred</font></b>(strict rule-in condition<i> (~B & A &~E) cannot do better</i> evaluate to <b> true</b> because <i>(~B)no current drug contraindicatedthere exists a contraindicated current med && Treatment_Diastolic_BP(62/null) && Treatment_Systolic_BP(134/null) && (~E)no (compellingly indicated not given and current drug not indicated)there exists a non-betablocker, non-ACE, non-clonidine , non (alpha blocker + BPH)drug to replace</i>)])
Maintain current drug choices and  continue to encourage patient adherence to his/her current regimen.

</ul>
</ul>
